Skip to main content
H.R. 1873 117th Congress House

Advancing Education on Biosimilars Act of 2021

Official title: To educate health care providers and the public on biosimilar biological products, and for other purposes.

Introduced: March 12, 2021 See on congress.gov
Health Drug safety, medical device, and laboratory regulationGovernment information and archivesHealth personnelLicensing and registrations
More subjectsShow fewer subjects
Medical educationPrescription drugs
Sign in to write a letter Sign in to watch
This bill died when the 117th Congress ended
It never became law before the 117th Congress (2021–2022) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 16, 2021
Referred to the Subcommittee on Health.
Mar 12, 2021
Referred to the House Committee on Energy and Commerce.
Mar 12, 2021
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action March 16, 2021

Referred to the Subcommittee on Health.

 Plain-English summary Congressional Research Service

Advancing Education on Biosimilars Act of 2021

This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.)

The FDA may also maintain and operate a website to provide educational materials about biological products.

 Related & companion bills 2
  • S 164 Identical bill Advancing Education on Biosimilars Act of 2021
  • HR 19 Lower Costs, More Cures Act of 2021
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
 Cosponsors 1
All 1 Democratic 1
D
Peters, Scott H.
California · Mar 12, 2021
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 1873: Advancing Education on Biosimilars Act of 2021. 117th Congress. Open America. https://openamerica.io/bill/117-HR-1873/
MLA
"H.R. 1873: Advancing Education on Biosimilars Act of 2021." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-HR-1873/.
Bluebook (legal)
H.R. 1873, 117th Cong. (2026), https://openamerica.io/bill/117-HR-1873/.
Markdown link
[H.R. 1873: Advancing Education on Biosimilars Act of 2021](https://openamerica.io/bill/117-HR-1873/)
Report a problem